High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2
Context: Patients with inflammatory bowel disease (IBD) were found to have the higher intestinal expression of Angiotensin-Converting Enzyme2 (ACE2) that could consequently increase susceptibility to COVID-19 infection.Objective: This study reports the outcomes of COVID-19 infection in a large cohort of IBD patients. We compare levels of serum ACE and IFN-α between COVID19 patients with and without IBD. We performed a cross-sectional retrospective multicenter study.Methods: We enrolled patients with IBD screened for SARS-COV-2 in six medical centres in Iran from June to November 2020. The blood samples were drawn to measure COVID-19 IgM and IgG, and serum levels of sACE2, sACE1, and interferon-α, regardless of suspicious symptoms have done the molecular test.Results: A total of 534 IBD patients were included in the study. Of these, 109 (20.0%) cases had detectable IgG and IgM against SARS-CoV-2. sACE2 levels were higher in IBD patients than controls, whereas ACE1and IFN-α levels were similar among groups.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2022 |
|---|---|
| Enthalten in: |
Archives of physiology and biochemistry - (2022) vom: 26. Mai, Seite 1-8 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shahrokh, Shabnam [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/13813455.2022.2080228 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM341403067 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM341403067 | ||
| 003 | DE-627 | ||
| 005 | 20240217231900.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/13813455.2022.2080228 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM341403067 | ||
| 035 | |a (NLM)35617972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shahrokh, Shabnam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High prevalence of SARS-Coronavirus-2 in patients with inflammatory bowel disease and the role of soluble angiotensin converting Enzyme2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Context: Patients with inflammatory bowel disease (IBD) were found to have the higher intestinal expression of Angiotensin-Converting Enzyme2 (ACE2) that could consequently increase susceptibility to COVID-19 infection.Objective: This study reports the outcomes of COVID-19 infection in a large cohort of IBD patients. We compare levels of serum ACE and IFN-α between COVID19 patients with and without IBD. We performed a cross-sectional retrospective multicenter study.Methods: We enrolled patients with IBD screened for SARS-COV-2 in six medical centres in Iran from June to November 2020. The blood samples were drawn to measure COVID-19 IgM and IgG, and serum levels of sACE2, sACE1, and interferon-α, regardless of suspicious symptoms have done the molecular test.Results: A total of 534 IBD patients were included in the study. Of these, 109 (20.0%) cases had detectable IgG and IgM against SARS-CoV-2. sACE2 levels were higher in IBD patients than controls, whereas ACE1and IFN-α levels were similar among groups | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Inflammatory Bowel disease | |
| 650 | 4 | |a SARS-CoV2 | |
| 650 | 4 | |a sACE | |
| 700 | 1 | |a Baradaran Ghavami, Shaghayegh |e verfasserin |4 aut | |
| 700 | 1 | |a Asadzadeh Aghdaei, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Parigi, Tommaso Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Farmani, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Danese, Silvio |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimi Daryani, Nasser |e verfasserin |4 aut | |
| 700 | 1 | |a Vossoughinia, Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Balaii, Hedieh |e verfasserin |4 aut | |
| 700 | 1 | |a Alborzi, Foroogh |e verfasserin |4 aut | |
| 700 | 1 | |a Khoramjoo, Seyed Mobin |e verfasserin |4 aut | |
| 700 | 1 | |a Khanabadi, Binazir |e verfasserin |4 aut | |
| 700 | 1 | |a Seyed Salehi, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Bastani, Ali |e verfasserin |4 aut | |
| 700 | 1 | |a Sharifi, Mohsen |e verfasserin |4 aut | |
| 700 | 1 | |a Safari, Mohammad Taghi |e verfasserin |4 aut | |
| 700 | 1 | |a Malekpour, Habib |e verfasserin |4 aut | |
| 700 | 1 | |a Sherkat, Ghazal |e verfasserin |4 aut | |
| 700 | 1 | |a Saberafsharian, Malihe |e verfasserin |4 aut | |
| 700 | 1 | |a Miri, Mohammad Bagher |e verfasserin |4 aut | |
| 700 | 1 | |a Moosavi, Seyed Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Anaraki, Fakhrosadat |e verfasserin |4 aut | |
| 700 | 1 | |a Nazemalhosseini-Mojarad, Ehsan |e verfasserin |4 aut | |
| 700 | 1 | |a Mohebbi, Seyed Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Shojaie, Sajad |e verfasserin |4 aut | |
| 700 | 1 | |a Pourhoseingholi, Mohamad Amin |e verfasserin |4 aut | |
| 700 | 1 | |a Zali, Mohammad Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Archives of physiology and biochemistry |d 1997 |g (2022) vom: 26. Mai, Seite 1-8 |w (DE-627)NLM075599813 |x 1744-4160 |7 nnns |
| 773 | 1 | 8 | |g year:2022 |g day:26 |g month:05 |g pages:1-8 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/13813455.2022.2080228 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 26 |c 05 |h 1-8 | ||